Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2011 1
2016 1
2017 1
2019 5
2020 11
2021 12
2022 5
2023 11
2024 17
2025 20
2026 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92 results

Results by year

Filters applied: . Clear all
Page 1
Guidelines of care for the management of acne vulgaris.
Reynolds RV, Yeung H, Cheng CE, Cook-Bolden F, Desai SR, Druby KM, Freeman EE, Keri JE, Stein Gold LF, Tan JKL, Tollefson MM, Weiss JS, Wu PA, Zaenglein AL, Han JM, Barbieri JS. Reynolds RV, et al. J Am Acad Dermatol. 2024 May;90(5):1006.e1-1006.e30. doi: 10.1016/j.jaad.2023.12.017. Epub 2024 Jan 30. J Am Acad Dermatol. 2024. PMID: 38300170
Conditional recommendations are made for topical clascoterone, salicylic acid, and azelaic acid, as well as for oral minocycline, sarecycline, combined oral contraceptive pills, and spironolactone. ...
Conditional recommendations are made for topical clascoterone, salicylic acid, and azelaic acid, as well as for oral minocycline, sar …
Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials.
Hebert A, Thiboutot D, Stein Gold L, Cartwright M, Gerloni M, Fragasso E, Mazzetti A. Hebert A, et al. JAMA Dermatol. 2020 Jun 1;156(6):621-630. doi: 10.1001/jamadermatol.2020.0465. JAMA Dermatol. 2020. PMID: 32320027 Free PMC article. Clinical Trial.
OBJECTIVE: To assess the safety and efficacy of clascoterone cream, 1%, a novel topical androgen receptor inhibitor, in 2 phase 3 randomized clinical trials (CB-03-01/25 and CB-03-01/26). ...At week 12, treatment success rates in …
OBJECTIVE: To assess the safety and efficacy of clascoterone cream, 1%, a novel topical androgen receptor inhibitor, in 2 phase 3 ran …
Clascoterone.
[No authors listed] [No authors listed] 2023 Jan 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Jan 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 36701501 Free Books & Documents. Review.
No information is available on the clinical use of clascoterone during breastfeeding. However, because it is poorly absorbed from the skin and 84% to 89% protein bound, amounts in breastmilk are probably low and would not be expected to cause any adverse effects in breastf …
No information is available on the clinical use of clascoterone during breastfeeding. However, because it is poorly absorbed from the …
Innovations in Acne.
Wafae BGO, Barbieri JS. Wafae BGO, et al. Dermatol Clin. 2025 Jan;43(1):11-25. doi: 10.1016/j.det.2024.08.002. Epub 2024 Sep 10. Dermatol Clin. 2025. PMID: 39542558 Review.
The mechanisms of action, pivotal trial data, and potential role in clinical practice are reviewed for emerging therapies such as 1726 nm laser, sarecycline, clascoterone, trifarotene, minocycline foam, and fixed-dose combination topicals. The clinical pipeline is also sum …
The mechanisms of action, pivotal trial data, and potential role in clinical practice are reviewed for emerging therapies such as 1726 nm la …
Clascoterone: First Approval.
Dhillon S. Dhillon S. Drugs. 2020 Nov;80(16):1745-1750. doi: 10.1007/s40265-020-01417-6. Drugs. 2020. PMID: 33030710 Review.
In August 2020, clascoterone cream 1% received its first approval in the USA for the topical treatment of acne vulgaris in patients 12 years of age or older. ...This article summarizes the milestones in the development of clascoterone leading to this first approval …
In August 2020, clascoterone cream 1% received its first approval in the USA for the topical treatment of acne vulgaris in patients 1 …
The primary role of sebum in the pathophysiology of acne vulgaris and its therapeutic relevance in acne management.
Del Rosso JQ, Kircik L. Del Rosso JQ, et al. J Dermatolog Treat. 2024 Dec;35(1):2296855. doi: 10.1080/09546634.2023.2296855. Epub 2023 Dec 26. J Dermatolog Treat. 2024. PMID: 38146664 Free article. Review.
CONCLUSIONS: To date, only combined oral contraceptives and oral spironolactone (both limited to female patients), oral isotretinoin and topical clascoterone (cortexolone 17alpha-propionate) modulate sebum production in patients with AV. ...
CONCLUSIONS: To date, only combined oral contraceptives and oral spironolactone (both limited to female patients), oral isotretinoin and top …
Hormonal Therapies for Acne: A Comprehensive Update for Dermatologists.
Smith CA, Gosnell E, Karatas TB, Deitelzweig C, Collins EMB, Yeung H. Smith CA, et al. Dermatol Ther (Heidelb). 2025 Jan;15(1):45-59. doi: 10.1007/s13555-024-01324-8. Epub 2025 Jan 3. Dermatol Ther (Heidelb). 2025. PMID: 39751745 Free PMC article. Review.
This review aims to update dermatologists on the Federal Drug Administration (FDA)-approved and off-label use of combined oral contraceptives (COC), clascoterone, spironolactone, and emerging hormonal therapies for acne treatment. METHODS: We reviewed current literature on …
This review aims to update dermatologists on the Federal Drug Administration (FDA)-approved and off-label use of combined oral contraceptive …
Update of the EuroGuiDerm evidence-based guideline for the treatment of acne-Short version.
Nast A, Al Wattar BH, Beylot Barry M, Brüggemann H, Bukvić Mokos Z, Caruana DM, Degitz K, Dessinioti C, Dréno B, Driessen RJB, Gollnick H, Hædersdal M, Katoulis A, Läuchli S, Lambert J, Layton AM, Micali G, Ochsendorf FR, Sathyapalan T, Stangeland KZ, Thomsen SF, Töröcsik D, Pennitz A. Nast A, et al. J Eur Acad Dermatol Venereol. 2026 Jul;40(7):1162-1172. doi: 10.1111/jdv.70331. Epub 2026 Mar 18. J Eur Acad Dermatol Venereol. 2026. PMID: 41847993 Free PMC article.
For which types of acne and patient groups should new topical treatments, including trifarotene and clascoterone, be recommended and with what strength of recommendation? Additionally, the updated guideline provides revised recommendations regarding: safety of benzoyl pero …
For which types of acne and patient groups should new topical treatments, including trifarotene and clascoterone, be recommended and …
Update to acne vulgaris treatment for Canadian practice.
Keow S, Xiong G, Abu-Hilal M. Keow S, et al. Can Fam Physician. 2025 Jul-Aug;71(7-8):455-466. doi: 10.46747/cfp.710708455. Can Fam Physician. 2025. PMID: 40730431 Free PMC article. Review.
MAIN MESSAGE: Topical therapies such as benzoyl peroxide, antibiotics, and fixed-dose combinations received strong recommendations, while retinoids, clascoterone, salicylic acid, and azelaic acid received conditional recommendations. Topical minocycline is not yet availabl …
MAIN MESSAGE: Topical therapies such as benzoyl peroxide, antibiotics, and fixed-dose combinations received strong recommendations, while re …
92 results